Selective Amylin Agonist

Eloralintide

Also called Elora or LY3841136 • Once-Weekly Amylin Research

Eloralintide is an investigational, long-acting peptide analog designed to selectively activate amylin receptors. Phase 2 data show substantial dose-dependent weight loss with a mechanism distinct from GLP-1 drugs, but it remains unapproved and long-term Phase 3 outcomes are still pending.

Satiety Signaling Weight-Loss Research Once Weekly Phase 3 Development

Protocol Snapshot

Quick reference before the deep dive

Verified Vendors

Eloralintide

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Clinical Range

1–9mg

Once weekly in the 48-week Phase 2 trial.

Community Start

500mcg

Low-end community starting dose, typically used once weekly.

Route

Subcutaneous

Once-weekly injection in published clinical research.

Trial Duration

48 Weeks

Phase 3 monotherapy studies are now recruiting.

Peptide Grade

GradeB

The clinical signal is strong: Phase 2 produced dose-dependent weight loss reaching about 20% at 48 weeks, with lower-dose tolerability close to placebo. Confidence is limited by the lack of completed Phase 3 data, long-term outcomes, and meaningful community experience outside controlled trials.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What Is Eloralintide?

Eloralintide, previously known as LY3841136 and informally shortened to Elora, is an investigational long-acting amylin receptor agonist developed by Eli Lilly. It is designed for once-weekly subcutaneous administration and is currently being studied for obesity and related metabolic conditions.

Amylin is a pancreatic hormone released alongside insulin. It contributes to satiety, meal-size control, and slower gastric emptying. Eloralintide targets this pathway without being a GLP-1, GIP, or glucagon agonist.

Eloralintide vs. GLP-1 Drugs

Retatrutide, tirzepatide, and semaglutide act through incretin-related pathways. Eloralintide instead uses selective amylin-receptor signaling, giving it a distinct appetite and weight-regulation mechanism.

That difference makes Eloralintide interesting as either an alternative or a complementary compound, but combination claims remain experimental. Lilly is studying it with tirzepatide; completed human results do not yet establish an independent stacking protocol.

Eloralintide Benefits

The strongest evidence comes from a 48-week randomized Phase 2 trial in 263 adults with obesity or overweight and at least one related comorbidity, without type 2 diabetes.

Dose-Dependent Weight Loss

Mean weight reduction ranged from 9.5% at 1mg to 20.1% at 9mg after 48 weeks, compared with 0.4% for placebo.

Satiety and Intake

The intended effect is lower calorie intake through amylin-mediated fullness and meal-size signaling.

Waist and BMI

Phase 2 treatment improved waist circumference and body-mass index alongside overall weight reduction.

Cardiometabolic Markers

Reported improvements included blood pressure, lipid profiles, glycemic control, and inflammatory markers.

Evidence Reality Check

The Phase 2 result is unusually strong for an amylin monotherapy, but Eloralintide is still investigational. Phase 3 studies began recruiting in 2026, and no FDA-approved product or validated grey-market protocol exists.

Mechanism of Action

Amylin Receptor Activation

Eloralintide mimics selected actions of native amylin through long-acting receptor agonism.

Satiety Signaling

Central appetite pathways receive stronger fullness signals, which can reduce meal size and calorie intake.

Gastric Emptying

Amylin biology can slow movement of food from the stomach, contributing to fullness and GI effects.

Receptor Selectivity

The program is designed for amylin-receptor activity with reduced off-target calcitonin-receptor signaling.

Protocol Planning

Dosing, cycling, and route preparation

Eloralintide Dosing Protocol

Fixed-Dose Phase 2 Arms

Dose

1mg, 3mg, 6mg, or 9mg

Timing

Once weekly

Duration

48 weeks

Route

Subcutaneous injection

Important

These are clinical trial arms, not a recommendation to begin at any fixed dose

Escalation Arms

Protocols

6→9mg and 3→6→9mg

Purpose

Evaluate tolerability and efficacy during gradual dose increases

Finding

Slower escalation reduced GI events and fatigue

Limit

Published results do not validate faster self-directed escalation

Status

Phase 3 protocols remain investigational

Eloralintide Reconstitution

10mg Vial

Diluent

2mL bacteriostatic water

Concentration

5mg/mL

1mg

20 units on a U-100 syringe

3mg

60 units on a U-100 syringe

Reconstitution Calculator

Handling Notes

Storage

Refrigerate after reconstitution and do not freeze

Inspect

Discard if the solution becomes cloudy or contains visible particles

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Early users commonly describe quieter appetite and smaller meals rather than stimulant-like energy.
Some report a smoother appetite profile than expected from GLP-1–based compounds, although direct comparisons are unreliable.
Weight-loss interest is high because the Phase 2 signal remained strong through 48 weeks without a clear plateau.

Negative Reports

Nausea, early fullness, fatigue, and reduced food tolerance are the most recurring concerns.
Community experience remains thin, and many reports cannot verify product identity or actual dose.
Using Eloralintide alongside an incretin can make under-eating, dehydration, and side-effect attribution harder to manage.

Stacking & Synergy

Potential Eloralintide pairings and tracking context

No completed human study establishes a grey-market Eloralintide stack. Introduce it alone when possible so appetite, GI response, fatigue, hydration, and weight change can be attributed clearly.

Eloralintide + Tirzepatide

Lilly is actively studying this pairing because amylin and incretin signaling may be complementary. Until results are complete, efficacy and tolerability remain unknown.

Eloralintide + Retatrutide

Mechanistically interesting but unvalidated. Overlapping appetite suppression and GI effects raise the risk of inadequate intake and poor tolerability.

Do Not Pair: Eloralintide + Cagrilintide

Do not combine these compounds. Both are long-acting amylin-pathway agonists, making the pairing redundant, unsupported by clinical evidence, and more likely to compound appetite suppression and GI side effects.

Free with login

Track in Journal

Eloralintide should be tracked with both outcome and tolerability markers because appetite changes can outpace the ability to maintain nutrition.

Dose, vial source, injection day, and escalation week.
Appetite, meal size, protein intake, hydration, nausea, and bowel changes.
Weight, waist circumference, and body-composition trend.
Strength, training performance, fatigue, sleep, and recovery.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

Eloralintide Side Effects

In Phase 2, the most common adverse events were mild to moderate gastrointestinal symptoms and fatigue. Events occurred more often at higher doses, while the 1mg and 3mg arms were closer to placebo. Slower escalation improved tolerability.

Phase 2 does not establish long-term safety, safety in uncontrolled stacks, or safety of unverified research products.

Commonly Monitored

Nausea, early fullness, vomiting, constipation, or diarrhea.
Fatigue or reduced training capacity.
Low food, fluid, protein, or electrolyte intake.
Injection-site irritation.

Stop and Reassess

Persistent vomiting, severe abdominal pain, or inability to hydrate.
Fainting, confusion, severe weakness, or symptoms of low blood sugar.
Allergic reaction or rapidly worsening injection-site symptoms.
Rapid unintended weight loss with clear strength or lean-mass decline.

Eloralintide Contraindications and Precautions

Do Not Use If You Have

Pregnancy or breastfeeding, because reproductive and developmental safety is not established.
An unidentified or unverified product with no credible identity, purity, or sterility testing.
An acute GI, pancreatic, gallbladder, metabolic, liver, kidney, or cardiovascular illness requiring evaluation.

Use Caution With

GLP-1 agonists, tirzepatide, retatrutide, cagrilintide, insulin, or other glucose-lowering medication.
Gastroparesis, severe reflux, chronic nausea, or prior GI intolerance to appetite-suppressing compounds.
Eating-disorder history or difficulty maintaining adequate protein and hydration.
Rapid weight loss without resistance training or body-composition monitoring.

Regulatory Status

Eloralintide is investigational and is not FDA approved. Phase 3 ENLIGHTEN studies are recruiting, including monotherapy and incretin add-on research. Grey-market vials are not approved clinical products.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Eloralintide is the newest high-profile compound to enter the peptide space, and interest has spiked as soon as RUO vendors began listing it.

Phase 2 human data offers some short-term reassurance on efficacy and tolerability, but it does not establish long-term safety. More critically, we cannot yet be confident that current research-grade material matches the compound and formulation used in clinical trials. Analytical methods are still maturing given how recently Eloralintide appeared, and at least one testing lab has told us they are not fully confident in their assays for it. At present, only one of our vetted suppliers carries the product.

If you choose to experiment, start at the low end of the dosing range and treat early availability as nothing more than availability—not validation. Our stance remains cautious. We will revise this view as better analytical methods, additional clinical data, and meaningful real-world experience become available.